Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HBOC-201
Therapeutic Area : Hematology
Study Phase : Undisclosed
Recipient : Jonathan H. Waters
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 16, 2018
Lead Product(s) : HBOC-201
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Recipient : Jonathan H. Waters
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HBOC-201
Therapeutic Area : Hematology
Study Phase : Undisclosed
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Protocol Using HBOC-201
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 18, 2016
Lead Product(s) : HBOC-201
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HBOC-201
Therapeutic Area : Hematology
Study Phase : Undisclosed
Recipient : Gadjah Mada University
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
June 19, 2013
Lead Product(s) : HBOC-201
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Recipient : Gadjah Mada University
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
